hcc
美 ['eɪtʃs'is'i] 
英 ['etʃs'i:s'i:]
- n.水硬水泥混凝土
- 网络肝细胞癌(hepatic cell carcinoma)；肝细胞肝癌；原发性肝癌
英汉解释
例句
For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treatment but is only possible in a minority of patients.
经动脉化疗栓塞是中期肝癌的主要治疗方法，但是它仅仅在少数病人中是可行的。
Hepatocellular carcinoma(HCC) is one of the most common malignant tumors, whose mechanism remains elusive.
原发性肝细胞癌（HCC）是常见的恶性肿瘤之一，其发生是一个多因素，多基因参与的复杂过程。
Heterogeneity in reporting means that these data may underestimate the rate of disease progression, particularly HCC development.
研究的异质性表明，这些数据可能低估疾病的进展速度，尤其是HCC的发生。
Hepatology Digest: From your experience, RFA is an efficient treatment for HCC. What are the indications and contraindications for RFA?
《国际肝病》：从您的经验来看，RFA是一种治疗肝细胞癌的有效方法。那么RFA的适应证和禁忌证有哪些？
For those patients with advanced HCC, who have had surgical resection, with the surgery impact the safety and efficacy of sorafenib ?
对于已进行了手术的晚期肝癌患者，手术会影响索拉非尼的安全性和疗效吗？
Incidence rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in the United States.
在美国，肝癌与肝内胆管癌发病率逐渐上升。
The aim of this review is to provide an up-to-date summary of recent advances in the field of HCC.
这篇综述的目的是为肝癌研究领域的最新进展做个最新的总结。
However, with advances in different treatment modalities for HCC, the incidence of extrahepatic metastasis appears to be increasing.
尽管如此，随着肝癌多学科综合治疗的发展，肝外远处转移的发生率逐渐增加。
International Digest: Most HCC is not diagnosed until the disease is at an advanced stage.
国际肝病：目前大多数的HCC治疗策略不能令人完全满意。
Although these patients receive systemic treatment including chemotherapy, HCC is generally recognized as a chemo-resistant tumor.
虽然这些病人得到了包括化疗在内的系统化治疗，肝癌通常被认为是化疗抵抗性肿瘤。
Incorporation of these molecular markers could help to improve organ allocation for HCV-HCC patients.
联合这些分子标志物能帮助提高器官在HCV-肝细胞癌患者中的分配。
Due to the proclivity of HCC for early micrometastases, immunosuppressive therapy can induce significant metastatic lesions.
由于癖性肝癌早期微小，可诱导免疫抑制治疗重大转移灶。
The current data suggest that there is no role for pre-transplant therapy for HCC within Milano criteria transplanted within six months.
目前也没根据米拉诺标准对肝癌移植前治疗对移植后六个月内的影响进行评估。
Background & Aims Hepatocellular Carcinoma (HCC) is one of the most common malignant tumor in the world.
背景和目的肝细胞肝癌（HCC）是常见的恶性肿瘤之一。
Objective To investigate the possibility of using telomerase as a tumor marker for human primary hepatocellular carcinomas (HCC).
目的明显研究端粒酶作为原发性肝技术细胞癌（HCC）肿瘤高血压标志物的可能性。
Hepatology Digest: At present, interventional therapy is still the more effective treatment strategy for unresectable HCC patients.
国际肝病：对于无法手术切除的肝癌病人，介入治疗仍是目前较有效的治疗方法。
HCC is a very diverse community. In this community, each one of us is a witness of Christ.
休士顿中国教会是一个多元化的群体。在这群体中，每一个人是一个见证人。
HCC( hepatocellular carcinoma) poses a significant disease burden in many parts of the world.
在世界各地，HCC（肝细胞肝癌）成为了严重的疾病负担。
BACKGROUND: Liver transplantation (LT) represents a curative treatment for small hepatocellular carcinoma (HCC).
背景：肝移植是小肝细胞癌的根治疗法。
At present, interventional therapy is still the more effective treatment strategy for unresectable HCC patients.
目前，介入治疗仍然是不能切除肝癌患者更有效的治疗策略。
Those guidelines also established noninvasive diagnostic criteria for HCC that the expert panel accepted for trial design.
指南中也制订了临床试验设计中专家组可接受的肝细胞癌非侵袭性诊断标准。
The median survival of HCC is less than 12 months from diagnosis, reflecting both late diagnosis and lack of effective therapy.
至确诊时起，肝细胞癌患者的平均中位生存期小于12个月，且预后不佳。
ABSTRACT: Objective To evaluate the prognostic value of surgical operation-related factors in patients with hepatocellular carcinoma (HCC).
摘要：目的分析外科医师手术操作对肝细胞癌（HCC）患者预后的影响因素。
Hepatology Digest: Do you think HCC is a major indication for living donor transplantation? Why or why not?
《国际肝病》：您认为HCC可以作为活体供肝肝移植的一个主要适应证吗？为什么？
The primary aim of the present study was to evaluate the impact of waitlist time on HCC recurrence.
先前的研究的最初的目的是评估在等待移植的时间对肝细胞癌复发的影响。
These signatures predict early and overall recurrence in patients with HCC, and complement findings from clinical and pathology analyses.
这些标记可预测HCC患者的早期与总体复发率，并且完善临床与病理分析的结果。
Objective: To explore the diagnosis, surgical treatment and outcome of hepatocellular carcinoma(HCC) with tumor thrombus in bile duct (BDT).
目的：探讨原发性肝癌合并胆管癌栓的诊断、外科治疗及疗效。
Treatment options for HCC include chemotherapy, chemoembolization, ablation and proton-beam therapy.
肝癌的治疗选择包括化疗、栓塞、消融和质子束疗法。
OBJECTIVE: To explore the role of arsenious acid on tumor recurrence in liver transplant patients with primary HCC extending Milan criteria.
目的：观察超出米兰标准的肝癌患者肝移植后应用亚砷酸全身化疗的对肿瘤复发的干预效果。
Methods The published papers on current situation and advance in the perioperative therapy of liver transplantation for HCC were reviewed.
方法采用文献回顾的方法对原发性肝癌肝移植围手术期治疗的现状及研究进展进行综述。
The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial.
目前还没有2期或3期试验对索拉非尼与多柔比星联用治疗晚期HCC患者进行评价。
Hepatocellular carcinoma(HCC) is one of malignant tumor having the highest death rate worldwide.
肝细胞肝癌是世界上病死率最高的恶性肿瘤之一。
The repeated injury and regeneration of liver cells, fibrosis and cirrhosis are three major stages of hepatocarcinogenesis.
在此过程中，肝脏反复发生的损伤和修复、肝纤维化和肝硬化是HCC发生过程中的几个关键阶段。
An older age at time of cirrhosis diagnosis and a higher BMI were negatively associated with the development of HCC.
诊断肝硬化时较大的年龄和较高的体重指数，与HCC的发生存在阴性相关。
Hepatocellular carcinoma (HCC) is an aggressive tumor with poor long-term prognosis.
肝细胞癌是一种预后很差的侵袭性肿瘤。
The team is currently testing small molecule inhibitors of LSF as a possible therapy for HCC in animal models.
该小组目前正在肝癌动物模型中验证LSF的小分子抑制剂，作为可能的治疗方法。
However, overall and HCC-specific survival were similar between the two groups.
然而，两组患者之间全部的存活率和HCC特异性存活率相似。
The projected frequency of liver failure and HCC due to NASH is expected to equal or surpass that due to hepatitis C.
由NASH导致的肝衰和HCC的高发病率预期将赶上或超过由丙型肝炎导致的疾病。
The Cleveland Clinic study established that NASH-induced cirrhosis is a much greater risk factor for HCC than previously thought.
克利夫兰临床部的研究明确了NASH相关性肝硬化，是进展为HCC的一个很重要的危险因素，强于以前我们对其的认识。
To investigate the correlation between the polymorphism of PTEN gene and the prognosis of HCC(Hepatocelluar Carcinoma) patients.
探讨PTEN基因多态性与家族聚集性肝癌预后的关系。
